LFCR Stock Analysis: Buy, Sell, or Hold?
LFCR - Lifecore Biomedical, Inc. Common Stock
$4.72
-0.01 (-0.21%)
âŧ
5d:
-5.79%
30d:
-4.65%
90d:
+3.74%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When LFCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LFCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LFCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LFCR is currently trading at $4.72, which is considered slightly high relative to its 30-day fair value range of $4.42 to $4.82.
Technical Outlook: Technically, LFCR is showing sideways momentum. Immediate support is located at $4.18, while resistance sits at $5.02.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.75 (+43.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LFCR is showing sideways momentum. Immediate support is located at $4.18, while resistance sits at $5.02.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.75 (+43.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.42 -
$4.82
Company Quality Score
49/100
(HOLD)
Options IV Signal
13th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 13th percentile)
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.0% below Wall St target ($6.75)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.42 -
$4.82
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$0.36
(7.7%)
Support & Resistance Levels
Support Level
$4.19
Resistance Level
$5.02
Current Trend
Sideways
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.66
Wall Street Target
$6.75
(+43.0%)
Revenue Growth (YoY)
-3.8%
Profit Margin
-23.8%
Share & Embed Analysis
Last updated: August 15, 2026 1:44 PM ET
Data refreshes hourly during market hours. Next update: 2:44 PM
Data refreshes hourly during market hours. Next update: 2:44 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LFCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$213 | 61 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$108 | 44 HOLD |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
ALKS
Alkermes Plc |
BUY
15 analysts |
$56 | 68 BUY |
